中国医学创新2025，Vol.22Issue(36)：9-13,5.DOI:10.3969/j.issn.1674-4985.2025.36.003
依洛尤单抗对急性ST段抬高型心肌梗死伴2型糖尿病患者的影响
The Impact of Evolocumab on Patients with Acute ST-Segment Elevation Myocardial Infarction and Type 2 Diabetes Mellitus
摘要
Abstract
Objective:To investigate the effect of Evolocumab on patients with acute ST-segment elevation myocardial infarction(STEMI)and type 2 diabetes mellitus(T2DM).Method:A total of 120 patients with acute STEMI and T2DM admitted to Xinyu Iron&Steel Group Central Hospital from January to June 2024 were selected as the research subjects and randomly divided into a control group(n=60)and an Evolocumab group(n=60)using the envelope drawing method.The control group received conventional treatment,while the Evolocumab group received Evolocumab in addition to conventional treatment.The cholesterol levels,inflammatory factors,left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptide(NT-proBNP),6-minute walking distance before treatment and after 12 months of treatment,and the incidence of major adverse cardiovascular events(MACE)were compared between the two groups.Result:After 12 months of treatment,residual cholesterol(RC)and TC in the Evolocumab group were significantly lower than those in the control group,while HDL-C was significantly higher(P<0.05);after 12 months of treatment,the levels of CRP,PCT,and IL-6 in the Evolocumab group were significantly lower than those in the control group(P<0.05);after 12 months of treatment,LVEF in the Evolocumab group was significantly higher than that in the control group,the 6-minute walking distance was significantly longer than that in the control group,and the NT-proBNP level was significantly lower than that in the control group(P<0.05);after 3 months of outpatient or telephone follow-up,the incidence of MACE in the Evolocumab group was significantly lower than that in the control group(P<0.05).Conclusion:Evolocumab effectively regulates lipid metabolism,reduces inflammatory response,improves cardiac function and exercise tolerance in patients with acute STEMI and T2DM.关键词
依洛尤单抗/心肌梗死/2型糖尿病/残余胆固醇Key words
Evolocumab/Myocardial infarction/Type 2 diabetes mellitus/Residual cholesterol引用本文复制引用
WEI Guyu,LIAO Wenjun,WANG Jianzhong..依洛尤单抗对急性ST段抬高型心肌梗死伴2型糖尿病患者的影响[J].中国医学创新,2025,22(36):9-13,5.基金项目
江西省卫生健康委科技计划项目(SKJP1220244325) （SKJP1220244325）
